News

Cystic Fibrosis Canada is extremely disappointed that people with cystic fibrosis (CF) in British Columbia will not be able to access lumacaftor/ivacaftor (ORKAMBI™) - a potentially life-changing drug - through the BC Pharmacare program, due to a recent decision to “close the books” on ORKAMBI™.

Cystic Fibrosis Canada is disappointed that people with cystic fibrosis (CF) in Canada are going to have wait even longer to gain access to ORKAMBI™, a potentially life-changing drug.

Cystic Fibrosis Canada is thrilled to welcome Party City Canada as a new national partner. Party City has 50 stores in Canada and operates in every province excluding, PEI, Quebec and Manitoba. Cystic Fibrosis Canada is one of five non-profit organizations to benefit this year from the Party City CARES cause marketing campaign.

MONTREAL, March 17^th, 2016 /CNW Telbec/ - Laurent Pharmaceuticals Inc. announced today the closing of a financing round led by Cystic Fibrosis Canada. Existing investors Aligo Innovation LP (previously MSBi Valorisation) and members of Anges Quebec, as well as other existing and new private investors, also participated in the round.

This investment will allow the preparation of the upcoming Phase 2 clinical trial with LAU-7b in cystic fibrosis (CF) patients, planned to start later this year in Canada and United States. LAU-7b is a once-a-day oral drug addressing the persistent and unresolved inflammation, a leading cause of lung tissue destruction in CF.

January 26, 2016 (Toronto, ON) ― Health Canada has issued a Notice of Compliance for the lumacaftor/ivacaftor combination drug ^PrORKAMBI^TM for use in Canada. This gives Canadians with cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation a chance to gain access to this breakthrough treatment. ^PrORKAMBI^TM could benefit around 1,550 Canadians living with CF.

A unique triple transplant has transformed the life of a 19-year-old Cystic Fibrosis patient who can now walk without an oxygen tank, exercise, eat full meals, and plan for the future.

TORONTO, October 21, 2015 – SickKids Foundation is pleased to announce a newly formed partnership with Cystic Fibrosis Canada which sees the creation of the Program for Individualized Cystic Fibrosis (CF) Therapy. The partnership includes a multi-year commitment to raise $7.5 million in support of CF research conducted at the Peter Gilgan Centre for Research and Learning at SickKids. This generous support will help SickKids researchers accelerate the discovery of new treatments and determine the most effective, personalized therapies for CF patients.

The 2014-2015 Bill Skelly and Ian F. McClure awards were presented to Kin Canada recipients on Saturday, August 22, 2015 at Kin Canada’s National Convention in Brandon, Manitoba. BILL SKELLY AWARD The Bill Skelly Awards, presented by Cystic…

Sunday, September 13, 2015 (Toronto, ON) — Ontarians can help support Cystic Fibrosis Canada by making a donation at any of the more than 650 LCBO stores throughout Ontario. Donation boxes for Cystic Fibrosis Canada will be displayed at LCBO…

CF Champion Madi Vanstone talks about the challenges of living with cystic fibrosis and KALYDECO®, and Regional Fund Developer for Cystic Fibrosis Canada Shannon Carkner provides further information on the disease on CHCH News.